6-Chloro-2,3-difluorotoluene | 1208077-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-Chloro-2,3-difluorotoluene
• 英文别名: 1-chloro-3,4-difluoro-2-methylbenzene
• CAS: 1208077-23-9
• 化学式: C₇H₅ClF₂
• mdl: MFCD12922582
• 分子量: 162.56
• InChiKey: XSXTVWMCENIWEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] COMBINATION THERAPY FOR PREVENTING ADDICTION<br/>[FR] POLYTHÉRAPIE POUR LA PRÉVENTION D'UNE ADDICTION
  申请人：AMYGDALA NEUROSCIENCES INC

  公开号：WO2019079209A1

  公开（公告）日：2019-04-25

  Disclosed is a novel combination therapy to reduce or prevent the acquisition of a conditioned response in a mammal comprising administering to the mammal a therapeutically effective amount of an aldehyde dehydrogenase (ALDH-2) inhibitor compound, such as a compound of Formula (I), in combination with a substance that produces the conditioned response, such as a medication containing a dopamine-producing agent such as an opioid, whereby the combination acts to reduce or prevent the acquisition of a conditioned response, and the deleterious side-effect of misuse, dependence, abuse, and/or addiction.

  揭示了一种新颖的联合疗法，用于减少或预防哺乳动物获得条件反射，包括向哺乳动物施用治疗有效量的醛脱氢酶（ALDH-2）抑制剂化合物，例如公式（I）中的化合物，与产生条件反射的物质结合，例如含有多巴胺生成剂的药物，如阿片类药物，从而使该组合作用于减少或预防条件反射的获得，以及滥用、依赖、滥用和/或成瘾的有害副作用。
• [EN] COMBINATION THERAPY FOR NICOTINE ADDICTION<br/>[FR] POLYTHÉRAPIE POUR LA DÉPENDANCE À LA NICOTINE
  申请人：AMYGDALA NEUROSCIENCES INC

  公开号：WO2020023792A1

  公开（公告）日：2020-01-30

  Disclosed is a combination therapy for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of an ALDH-2 inhibitor, such as a compound of Formula (I), in combination with an amount of the nicotinic acetylcholine receptor agonist, varenicline. The disclosure further relates to methods and pharmaceutical compositions useful with the combination therapy.

  揭示了一种用于减少哺乳动物尼古丁成瘾或帮助戒烟或减少烟草使用的联合疗法，包括向该哺乳动物施用一定量的ALDH-2抑制剂，如式（I）化合物，与一定量的尼古丁乙酰胆碱受体激动剂维拉尼克林相结合。该公开还涉及与该联合疗法有用的方法和药物组合。
• AZEPINE INHIBITORS OF JANUS KINASES
  申请人：Arvanitis Argyrios G.

  公开号：US20120329782A1

  公开（公告）日：2012-12-27

  The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了一种可以调节Janus激酶活性的化合物，这些化合物在治疗与Janus激酶活性相关的疾病方面非常有用，例如免疫相关疾病、皮肤疾病、髓系增生性疾病、癌症和其他疾病。
• N-[4-(2-OXO-1,2-DIHYDRO-PYRIDIN-4-YL)-BENZYL]-BENZAMIDE DERIVATIVES AS ALDH-2 INHIBITORS FOR THE TREATMENT OF ADDICTION
  申请人：Gilead Sciences, Inc.

  公开号：EP2993170A1

  公开（公告）日：2016-03-09

  Disclosed are N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives which are useful as human mitochondrial aldehyde dehydrogenase (ALDH-2) inhibitors for treating chemical dependency on dopamine-producing agents such as cocaine, opiates, amphetamines, nicotine and alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of said compounds and methods of using the compounds in the treatment of addiction.

  本发明公开了N-[4-(2-氧代-1,2-二氢吡啶-4-基)-苄基]-苯甲酰胺衍生物，该衍生物可作为人类线粒体醛脱氢酶（ALDH-2）抑制剂，用于治疗对多巴胺产生剂（如可卡因、阿片剂、苯丙胺、尼古丁和酒精）的化学依赖性。还公开了包含治疗有效量的所述化合物的药物组合物以及使用这些化合物治疗成瘾的方法。
• US8563541B2
  申请人：——

  公开号：US8563541B2

  公开（公告）日：2013-10-22